AB SCIEX Wins New Product Innovation Award in Asia Pacific
News Oct 30, 2014
AB SCIEX was awarded this month the 2014 Asia Pacific Mass Spectrometry New Product Innovation Award by Frost & Sullivan.
The award candidates are selected through extensive research with industry experts, market participants, end-users, and other value chain players and supplemented with secondary information and Frost & Sullivan’s own proprietary industry research. AB SCIEX excelled in revolutionary technology in the mass spectrometry space; relevance and market acceptance of recent new products, quality, performance, reliability, and competitive advantage; as well as product support and value-added services for customers.
AB SCIEX has introduced several new innovative solutions recently and, in 2014 alone, AB SCIEX brought to the market the enhanced Triple Quad™ 3500 System, a basic mass spectrometry system widely used to meet the increasing demands for food and environmental testing; new TripleTOF® 6600 System with SWATH™ Acquisition 2.0, a revolutionary solution for quantitative proteomics; CESI 8000 System, a breakthrough technology for biologics characterisation; and a range of software including MasterView® for screening, identification and quantification of unexpected contaminants in food samples, and BioPharmaView™ for data analysis in the area of drug development.
"We are extremely honoured to be bestowed the award from Frost & Sullivan. It is truly a recognition of our continued innovation in the mass spectrometry industry," commented Johnson Ho, Vice President & General Manager, AB SCIEX, Asia Pacific. "Over the last several years AB SCIEX has made significant investment in Singapore, which reconfirms our unfaltering commitment to the market and our role as a trusted partner with scientists across the region."
Frost & Sullivan tracks over 250,000 companies annually to identify best practices and excellence in growth strategy, competitive strategy, customer satisfaction and technology innovation, among others.
AB SCIEX was also honored with the Global Market Share Leadership Award for Mass Spectrometry from Frost & Sullivan in 2013.
In new studies a novel oxygen-delivery therapeutic restored the function of oxygen-starved heart tissue in an animal model of global hypoxia. Unlike its experimental predecessors, the new drug does not appear to cause systemic side effects or overcorrect with excessive blood oxygenation, which can itself be toxic. Instead, the new drug delivers its precious oxygen cargo only to the tissues that need it most.READ MORE